Tavokinogene Telseplasmid, Pembrolizumab Combo Promising in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

Source: cancernetwork, November 2020

Tavokinogene telseplasmid (Tavo) in combination with pembrolizumab (Keytruda) in patients with rigorously defined anti-PD-1 checkpoint resistant metastatic melanoma led to a 30% overall response rate (ORR) in the first 54 patients enrolled, according to new positive interim data from the registration-enabled phase 2b KEYNOTE-695 clinical trial.

This interim investigator assessed ORR is much higher than the primary efficacy end point for the study, which is a 20% ORR determined by blinded independent review.

The study enrolled rapidly progressing patients with a median interval of 1.2 months between the last dose of anti-PD-1 and study treatment.